Serum tau protein elevation in migraine: a cross-sectional case–control study

Table 3 Serum t-Tau, NfL, GFAP, and UCH-L1 concentrations for HC, EM, and CM

[A] Biomarker	Healthy control (HC) n = 42	Episodic migraine without aura (EMO) n = 49	Episodic migraine with aura (EMA) n = 43	p-values ^a	Multiple variable adjusted p-value^b
t-tau	0.200 (0.114 to 0.288)	0.332 (0.234 to 0.449)^c	0.291 (0.184 to 0.486)^c	0.004*	0.002*
NfL	7.5 (6.0 to 9.0)	7.2 (5.9 to 8.0)	6.6 (5.4 to 10.0)	0.637	0.769
GFAP	69.4 (54.7 to 90.0)	66.8 (53.0 to 95.0)	70.3 (48.5 to 97.0)	0.965	0.696
UCH-L1	0.120 (0.120 to 0.357)	0.120 (0.120 to 5.17)	0.120 (0.120 to 4.645)	0.210	0.150
[B] Biomarker	Healthy control (HC) n = 42	Chronic migraine without prophylaxis (CM-) n = 48	Chronic migraine with prophylaxis (CM +) n = 45	p-values^a	Multiple variable adjusted p-value^b
t-tau	0.200 (0.114 to 0.288)	0.322 (0.181 to 0.463)^c	0.293 (0.126 to 0.375)	0.012*	0.015*
NfL	7.5 (6.0 to 9.0)	7.8 (5.4 to 12.0)	7.3 (5.1 to 11.0)	0.693	0.201
GFAP	69.4 (54.7 to 90.0)	78.2 (56.7 to 106.0)	65.8 (49.0 to 100.0)	0.490	0.313
UCH-L1	0.120 (0.120 to 0.357)	0.241 (0.120 to 2.446)	0.120 (0.120 to 1.025)	0.083	0.104

Values are expressed as median (interquartile range) in pg/mL
^aP-values are estimated with an independent-samples Kruskal–Wallis test with a Dunn’s post-hoc test with Bonferroni correction for multiple comparisons
^bP-values are estimated with a Quade nonparametric ANCOVA adjusting for age, sex, and body mass index
^*p-value < 0.05
^cIndicates statistical elevation vs. controls

ISSN: 1129-2377